Skip to content
Menu

Argus Research Reiterates Buy on Zimmer Biomet Holdings, Maintains $125 Price Target

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Argus Research analyst David Toung reiterates Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and maintains $125 price target.

Argus Research analyst David Toung reiterates Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and maintains $125 price target.

Read at benzinga.com

← All stock news